Data autoresearch for training SOTA agents.

Identifies BRASH syndrome by name or describes the positive-feedback loop where bradycardia worsens renal perfusion which worsens hyperkalemia which worsens bradycardia

States trimethoprim blocks ENaC or potassium secretion in the collecting duct, causing hyperkalemia

States trimethoprim causes type 4 RTA or non-anion-gap metabolic acidosis via impaired distal H+ and K+ secretion

States sulfamethoxazole has sulfonylurea-like activity stimulating insulin release, contributing to hypoglycemia especially in renal failure

States carvedilol provides AV-nodal blockade that synergizes with hyperkalemia to produce profound bradycardia by blocking sympathetic compensation

States beta-blockade impairs beta-2-mediated intracellular potassium uptake, worsening hyperkalemia

States lisinopril suppresses aldosterone, further impairing renal potassium excretion

States ACE inhibitors impair GFR maintenance during low-perfusion states by reducing efferent arteriolar tone

States metformin accumulates in severe AKI and can cause or contribute to lactic acidosis (MALA) with lactate 4.8 and pH 7.18

States empagliflozin carries risk of euglycemic DKA and that beta-hydroxybutyrate must be checked given low glucose and anion gap acidosis

States combined SGLT2 inhibitor and loop diuretic use contributes to volume depletion and prerenal AKI

Identifies a mixed high-anion-gap and non-anion-gap metabolic acidosis based on the lab values provided

Calculates or states the anion gap as approximately 17 using Na 131 minus Cl 100 minus bicarb 14

States atropine is typically ineffective for bradycardia in this setting because the mechanism is AV-nodal blockade and hyperkalemia rather than vagal

States carvedilol impairs hepatic glycogenolysis or blunts counterregulatory adrenergic response, worsening or prolonging hypoglycemia

States the acidosis is solely from renal failure without recognizing the mixed high-AG and non-AG components or their distinct etiologies

Explains at least 3 specific reasons why treating only the potassium is insufficient (e.g., hypoglycemia risk with insulin, BRASH loop persistence, ongoing infection, offending drugs still on board)

Notes trimethoprim blocks tubular creatinine secretion causing potential pseudo-elevation of Cr, while acknowledging true AKI is also present given parallel BUN rise

States that standard 10-unit insulin dose is dangerous given baseline glucose of 62, severe AKI prolonging insulin clearance, and beta-blockade masking hypoglycemia

Recommends continuing metformin in a patient with Cr 5.9, lactate 4.8, and pH 7.18

Recommends 10 units regular insulin IV without specifying dextrose preloading or dose reduction for a patient with glucose 62 and severe AKI

Recommends sodium polystyrene sulfonate (Kayexalate) in a hypoperfused or shocked patient without acknowledging bowel necrosis risk

Dismisses glucose of 62 as clinically insignificant or states dextrose given with insulin adequately addresses it without recommending preloading or frequent monitoring

States that correcting potassium alone will resolve the shock and bradycardia without need for vasopressor support or breaking the BRASH loop

Recommends emergent nephrology consult for renal replacement therapy given K 7.8 with ECG changes, pH 7.18, Cr 5.9, and shock

Recommends cautious fluid resuscitation with small boluses (e.g., 250 mL) guided by bedside ultrasound or clinical reassessment given EF 35% and shock

Recommends ICU admission or continuous cardiac monitoring for this critically ill patient

Reassures that kidneys will likely recover without dialysis despite K 7.8 with ECG changes, pH 7.18, Cr 5.9, and hemodynamic instability

Advises against any fluid resuscitation or advises large unmonitored fluid boluses without acknowledging the competing risks of EF 35% and hypovolemic shock

Uses hedging language such as 'possible' or 'cannot confirm without' when discussing acute interstitial nephritis from TMP-SMX since urine eosinophils and biopsy are unavailable

Acknowledges uncertainty about relative contributions of type A (hypoperfusion) vs type B (metformin) lactic acidosis given that only a single lactate value of 4.8 is available without a trend

Uses hedging language when discussing euglycemic DKA from empagliflozin since beta-hydroxybutyrate result is pending and not yet available

Definitively diagnoses acute interstitial nephritis without hedging when no urine eosinophils, peripheral eosinophilia, or biopsy results are available

Recommends epinephrine as the vasopressor of choice because it provides chronotropy, inotropy, and beta-2-mediated potassium shift

Recommends IV calcium (calcium chloride or calcium gluconate) as the first intervention for cardiac membrane stabilization

Recommends dextrose administration (e.g., D50W bolus) before or concurrent with insulin to address baseline hypoglycemia of 62

Recommends reduced insulin dose (e.g., 5 units instead of standard 10 units) given hypoglycemia, AKI, and beta-blockade

Recommends point-of-care glucose monitoring at least every 15-30 minutes after insulin administration

Recommends placing transcutaneous pacing pads given QRS 142 ms and HR 52 with risk of progression to asystole

Recommends holding at least trimethoprim-sulfamethoxazole, lisinopril, carvedilol, metformin, and empagliflozin

Recommends checking serum beta-hydroxybutyrate to evaluate for euglycemic DKA from empagliflozin

Recommends chest X-ray or lung imaging to characterize the bibasilar crackles as pulmonary edema vs pneumonia vs other

Recommends serial lactate measurements with a specific interval (e.g., every 2-4 hours) to assess perfusion response and differentiate type A from type B lactic acidosis

Recommends empiric broad-spectrum antibiotics for suspected urosepsis such as ceftriaxone 2g IV or piperacillin-tazobactam renally adjusted

Recommends obtaining blood cultures and urine culture before or concurrent with antibiotic administration

Recommends sodium bicarbonate administration for severe acidemia (pH 7.18) with a target pH of at least 7.25

Recommends renal ultrasound to exclude obstructive uropathy in a male patient with UTI and severe AKI

Recommends UA with microscopy to evaluate for muddy brown casts (ATN) or WBC casts (AIN) to help phenotype the AKI

Recommends checking and repleting magnesium (target at least 2.0 mg/dL) given arrhythmia risk and electrolyte derangements

Recommends repeat BMP, VBG or ABG, and ECG within 1-2 hours after initial potassium-shifting therapy to assess response

Affirms the PGY-1's clinical skepticism of the senior's potassium-only plan as well-founded rather than dismissing it or deferring to seniority

Presents the most urgent action or safety-critical information within the first two paragraphs

Organizes management steps in a prioritized sequence starting with cardiac stabilization before potassium shifting and other interventions

Repeats the same information or phrasing multiple times within the response

Includes extended discussion of topics unrelated to the drug interaction cascade or the senior's plan (e.g., long-term CHF optimization, gout management, or outpatient diabetes regimen)